MARY CARRASCO: Open Payments
NPI 1255981122 · DENVER, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$202 in 10 payments from 5 companies in 2025. Trend: 2023 $925 · 2024 $348 · 2025 $202
Food & beverage: $202
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 4 | $89 |
| Sumitomo Pharma America, Inc. | 2 | $39 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $31 |
| Amgen Inc. | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
Products named: LINZESS, GEMTESA, QULIPTA, XIFAXAN, REPATHA, REXULTI.
Industry payments across CO — which companies pay providers there.
